ANPCF Stock - Cellbxhealth PLC
Unlock GoAI Insights for ANPCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.86M | $2.19M | $1.04M | $1.01M | $762,000 |
| Gross Profit | $1.78M | $-408,000 | $613,000 | $711,000 | $597,000 |
| Gross Margin | 62.2% | -18.7% | 58.9% | 70.2% | 78.3% |
| Operating Income | $-15,096,000 | $-21,759,000 | $-24,207,000 | $-17,235,000 | $-13,731,000 |
| Net Income | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 | $-11,606,000 |
| Net Margin | -497.0% | -921.0% | -2083.2% | -1481.9% | -1523.1% |
| EPS | $-0.05 | $-0.08 | $-0.09 | $-0.07 | $-0.07 |
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
Visit WebsiteEarnings History & Surprises
ANPCFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 9, 2025 | — | $-0.04 | — | — |
Q2 2025 | May 28, 2025 | — | $-0.01 | — | — |
Q4 2024 | Oct 24, 2024 | — | — | — | — |
Q3 2024 | Sep 26, 2024 | — | $-0.02 | — | — |
Q2 2024 | Jun 5, 2024 | — | $-0.02 | — | — |
Q1 2024 | Mar 19, 2024 | — | $-0.03 | — | — |
Q1 2024 | Feb 7, 2024 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.05 | — | — |
Q2 2023 | Apr 21, 2023 | — | $-0.06 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.02 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.03 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.05 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.03 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.04 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.02 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.05 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.02 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.03 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.03 | — | — |
Latest News
Frequently Asked Questions about ANPCF
What is ANPCF's current stock price?
What is the analyst price target for ANPCF?
What sector is Cellbxhealth PLC in?
What is ANPCF's market cap?
Does ANPCF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ANPCF for comparison